Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Emles Advisors Announces Closure of Six Funds PR Newswire NEW YORK, Sept. 16, 2022 NEW YORK, Sept. 16, 2022 /PRNewswire/ -- Due to the inability to attract sufficient investment assets and based...
Samaritan Pharmaceuticals Inc. (AMEX:LIV): ? -- Trial Designed to Tackle HIV Drug Resistance (One or More of a Patient's Current HIV Drug Regime Stops Working Leading to a Lack of Treatment...
Samaritan Pharmaceuticals Inc. (AMEX:LIV): ? -- Data Shows 0.4 log10 Difference Between the High-Dose and the Placebo Control Group ? -- Dose dependent relationship in the number of subjects...
Samaritan Pharmaceuticals Inc. (AMEX:LIV): ? -- Clears Clogged Arteries ? -- Raises HDL ? -- Reduces CK Enzyme Marker: Suggesting It Improves, Hypercholesterolemia-Related Heart Suffering...
Samaritan Pharmaceuticals (AMEX:LIV): ? -- Completed Phase II Stage 1 (10 Day Monotherapy) ? -- Expect to Report Stage I Preliminary Results at Shareholders Meeting May 31st ? -- Expect...
The Samaritan Foundation and Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today on National DNA day, it is driven to raise money to bring its...
Samaritan Pharmaceuticals Inc. (AMEX:LIV) ? -- David W. Munno, Merrill Lynch VP of biotechnology, stated, "Large-cap biotech firms need some blockbuster products for meaningful growth which is...
Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today, its shareholders are invited to the Annual Shareholders Meeting on Wednesday, May 31, 2006 10 a.m. at...
Samaritan Pharmaceuticals, Inc. (AMEX:LIV) is pleased to announce that its subsidiary Samaritan Pharmaceuticals Europe, S.A. has received notification by the National Pharmaceuticals Organization...
Samaritan Pharmaceuticals Inc. (AMEX:LIV): ? -- PII/III HIV Oral Entry Inhibitor Drug ? -- Cardiovascular Drug SP-1000 ? -- Alzheimer's Drug SP-233 ? -- Alzheimer's Blood Diagnostic ?...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
